Biopharmaceutical company Gilead Sciences reported total revenues of approximately 27.1 billion U.S. dollars in 2023, almost the same amount like in the preceding two years. Product sales accounted for nearly all of the company’s total worldwide revenues.

Gilead’s HIV product portfolio Gilead Sciences announced total product sales of around 27 billion U.S. dollars in 2023, of which around 60 percent were derived from its HIV division. Sales of its top HIV treatment Biktarvy generated 11.9 billion U.S. dollars in the same year. The company continues to grow its HIV division, but there were also year-on-year sales declines for two of its top products: Genvoya and Odefsey. Gilead cannot become too reliant on its HIV division and is looking to develop new products and repurpose existing products for new indications.

Curing the COVID-19 pandemic Drug repurposing is the process of exploring existing treatments to discover new therapeutic benefits. In the race to develop an effective treatment for COVID-19, one potential medication that has gained attention was remdesivir. Originally developed by Gilead Sciences for use against Ebola, clinical trials have shown remdesivir’s safety and efficacy in certain groups of COVID-19 patients. Especially before vaccines became available, the spotlight was on Gilead: it has seen a huge change in its market capitalization.

This statistic shows the top products of biopharmaceutical company Gilead Sciences from 2021 to 2023, based on revenue. Gilead Sciences Inc. is headquartered in California and is specialized in discovering, developing and commercializing therapeutics. In 2023, Gilead Sciences' COVID-19 treatment Veklury (remdesivir) generated some 2.2 billion U.S. dollars in revenue, a significant decrease compared to 5.6 billion in 2021.

The net income of Gilead Sciences with headquarters in the United States amounted to 5.6 billion U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total increase by approximately 249 million U.S. dollars. The trend from 2019 to 2023 shows, however, that this increase did not happen continuously.

Gilead Sciences reported $136.16B in Market Capitalization this March of 2025, considering the latest stock price and the number of outstanding shares.Data for Gilead Sciences | GILD - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last March in 2025.

Gilead Sciences exceeded Wall Street expectations with strong Q4 results, driven by a surge in HIV drug sales, showcasing a solid revenue increase and a resilient portfolio.

Gilead Sciences reported $5.99B in Gross Profit on Sales for its fiscal quarter ending in December of 2024. Data for Gilead Sciences | GILD - Gross Profit On Sales including historical, tables and charts were last updated by Trading Economics this last March in 2025.

Gilead Sciences reported $1.78B in Net Income for its fiscal quarter ending in December of 2024. Data for Gilead Sciences | GILD - Net Income including historical, tables and charts were last updated by Trading Economics this last March in 2025.

The operating profit of Gilead Sciences with headquarters in the United States amounted to 7.6 billion U.S. dollars in 2023. The reported fiscal year ends on December 31.Compared to the earliest depicted value from 2019 this is a total increase by approximately 3.31 billion U.S. dollars. The trend from 2019 to 2023 shows, however, that this increase did not happen continuously.

Gilead Sciences reported $59B in Assets for its fiscal quarter ending in December of 2024. Data for Gilead Sciences | GILD - Assets including historical, tables and charts were last updated by Trading Economics this last March in 2025.

This statistic shows the sales per employee of selected U.S.-based biotech and drugs companies as of the 3rd quarter of 2024, or the latest quarter available. As of Q3 2024, U.S. company Gilead Sciences reported about 1.57 million U.S. dollars of sales per employee for the trailing twelve months.

Gilead Sciences reported $2.45B in Operating Profit for its fiscal quarter ending in December of 2024. Data for Gilead Sciences | GILD - Operating Profit including historical, tables and charts were last updated by Trading Economics this last March in 2025.

Gilead Sciences stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.

This statistic displays the projected 2022 revenue for selected top drugs approved in the U.S. in 2018. Biktarvy, developed by Gilead Sciences, is estimated to generate some five billion U.S. dollars in annual revenue in 2024.

Gilead Sciences reported $3.11B in EBIT for its fiscal quarter ending in December of 2024. Data for Gilead Sciences | GILD - Ebit including historical, tables and charts were last updated by Trading Economics this last March in 2025.

By 2024, Yescarta, a Car-T therapy from Gilead Sciences, is expected to have the largest revenue in both regions with 966 million U.S. dollars in the United States and 321 million U.S. dollars in Europe. This statistic shows the estimated 2024 revenues for selected anti-CD19 Car-T therapy in the U.S. and in Europe.

Gilead Sciences reported $5.12B in Operating Expenses for its fiscal quarter ending in December of 2024. Data for Gilead Sciences | GILD - Operating Expenses including historical, tables and charts were last updated by Trading Economics this last March in 2025.

Among top pharmaceutical companies in 2022, Novo Nordisk had the highest gross margin, followed by Gilead Sciences and Eli Lilly. Novo Nordisk’s gross margin in that year was nearly 83 percent, while Gilead's and Eli Lilly's gross margin at that time was about 77-79 percent. Gross margin here is defined as the revenue of a company less the cost of goods sold, divided by revenue. Gross margin is a representation of profit. The higher the gross margin, the more power a company has to raise prices.

Top pharmaceutical companies

Pharmaceutical companies can be ranked in other ways as well. In 2022, Pfizer and AbbVie were the top-ranked pharmaceutical companies based on prescription sales. Research and development spending is another way in which pharmaceuticals can be ranked. Among global top companies, Roche and J&J were the leading pharmaceutical companies based on research and development spending as a portion of revenue in 2022.

Company spotlight: Novartis

Novartis, a pharmaceutical company based in Switzerland, was the sixth leading biotech and pharmaceutical company based on market capitalization as of 2023. Novartis has experienced distinct regional successes in Europe and in the United States being the top regional revenue generators for Novartis.